Literature DB >> 1970766

Pharmacokinetics and metabolism of the pharmacologically active 4'-hydroxylated metabolite of propranolol in the dog.

D D Christ1, U K Walle, J E Oatis, T Walle.   

Abstract

The disposition of 4'-hydroxypropranolol (HOP) was determined after iv administration to dogs (2 mg/kg; N = 5) and the pharmacokinetic parameters were calculated from plasma measurements. The clearance of HOP, 66 +/- 6 ml/min/kg (mean +/- SE), was considerably higher than that of propranolol previously determined, suggesting extrahepatic as well as hepatic clearance of HOP. The plasma half-life of HOP, 77 +/- 6 min, was shorter than that of propranolol. Although HOP is considerably less lipophilic than propranolol, its volume of distribution, 6.4 +/- 0.8 liter/kg, surprisingly, was larger. Like propranolol, HOP appeared to be cleared entirely by metabolism. Whereas propranolol is metabolized mainly by oxidation, HOP was metabolized to sulfate (HOPS) and glucuronic acid (HOPG) conjugates. The plasma half-lives of these conjugates were 2 to 3 times longer than for HOP, reflecting a slow, continuous formation from HOP. This was established for HOPS by iv administration of synthetic HOPS. Morover, after HOP administration both formation and renal clearance of HOPS were stereoselective in favor of the R-enantiomer. In summary, the main conclusion of this study is that the large volume of distribution as well as high clearance through sulfation and glucuronidation may explain the low plasma HOP levels observed during propranolol therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970766

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

1.  Stereoselective sulphate conjugation of racemic terbutaline by human liver cytosol.

Authors:  T Walle; U K Walle
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

2.  Investigation of the biochemical effects of renin inhibition in normal volunteers treated by an ACE inhibitor.

Authors:  D Chauveau; T T Guyenne; F Cumin; G Chatellier; P Corvol; J Ménard
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

3.  Rapid in-plate screening of biotransformation products in single zebrafish embryos.

Authors:  Anton Ribbenstedt; Jonathan P Benskin
Journal:  RSC Adv       Date:  2021-08-16       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.